Vesalius Cardiovascular is a Canadian medical device venture founded in 2016 in Vancouver, British Columbia. The company specializes in designing, developing and commercializing biomedical devices for the treatment of cardiovascular disease, specifically mitral valve regurgitation (MR). Our devices will be introduced percutaneously to the heart, eliminating the need for open heart surgery and the related risks. The procedure can be performed by a Cardiovascular Interventionalist (Cardiologist or Cardiac Surgeon). Vesalius Cardiovascular is the result of several years of intensive private research and investigation. The inventor behind Vesalius Cardiovascular is Dr. Peter Skarsgard, a Vancouver-based Cardiac Surgeon, and Head of the Division of Cardiovascular Surgery at Vancouver General Hospital. The venture will be managed as a lean Research and Development Initiative, with a scientific feedback and inputs from our Board of some of BC's most prominent clinicians. Currently, our scientific team includes:- Peter Skarsgard (MD), cardiac surgeon and Head of Cardiovascular Surgery at VGH- Jacqueline Saw (MD), interventional cardiologist, expert and KOL in percutaneous device delivery- Richard Cook (MD), cardiac surgeon and Head of Minimally Invasive Cardiac Surgery at VGH- Christopher Durkin (MD), Anaesthesiologist with advanced expertise in 3D echo for intracardiac structural disease- Ian McDougall (BASc - Mech Eng), a local biomedical device engineering expert deeply involved in startupsVesalius Cardiovascular is currently developing Calla, a biomedical device that can be introduced percutaneously to the heart, for the treatment of degenerative MR (due to mitral valve prolapse), the most common variety of MR. The principles of surgical mitral valve repair are utilized, but sternotomy, heart-lung bypass, and cardiac arrest - components of an open heart operation - are not required.